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Abstract 
 Among non-communicable diseases, cancer is the second leading 
cause of death worldwide. In Jordan, it is the second leading cause of death. 
Fatigue is the most reported symptom among cancer patients. The purpose of 
this study was threefold: (1) to explore the prevalence of fatigue as a side 
effect of cancer chemotherapy (2) to examine the impact of chemotherapy on 
fatigue, and (3) to investigate psychological factors (depression and anxiety) 
that correlate with fatigue. A one group before and after quasi-experimental 
design was used to conduct this study. The Integrated Fatigue Model (IFM) 
was used to guide the study. A Convenience sampling technique was used to 
recriut78 participants diagnosed with cancer and treated with chemotherapy 
as the primary treatment. The sample was collected from two well-known 
Jordanian hospitals. Fatigue was measured using the Piper Fatigue Scale 
(PFS) and the psychological variables (depression and anxiety) were 
measured using Hospital Anxiety and Depression Scale (HADS). Findings 
revealed an increase incidence of fatigue after a chemotherapy course. Also 
revealed was a statistically significant difference between pre and post 
chemotherapy fatigue mean total scores as well as behavioral, affective, 
sensory and cognitive dimensions. It was found that depression and anxiety 
have a positive relationship with fatigue. Depression explained 46% of 
fatigue score variance. Furthermore, anxiety explains 3.6% of the variance in 
fatigue scores. It could be concluded that fatigue is a prevalent symptom 
among cancer patients receiving chemotherapy. Depression and anxiety were 
identified as possible predictors of fatigue among cancer patients receiving 
chemotherapy. 
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Introduction 
 Statistics by the World Health Organization (WHO) indicate that 
cancer is the second leading cause of death worldwide from non-
communicable diseases (WHO, 2015b). Approximately 8.4M have died from 
cancer and its complications by 2012. The figure is expected to rise by 70% 
over the next 20 years (WHO, 2015a).  
Cancer is the second leading cause of death in Jordan, accounting for 14.6% 
of the total mortality rate. Between 2000 and 2010, the number of newly 
discovered cancer cases in Jordan increased by 46%  (Tarawneh, Nimri, 
Arkoob, & Zaghal, 2010).  
In the last decade, many studies have emphasized the prevalence of fatigue 
among cancer patients. There is strong evidence suggesting that fatigue is a 
prevalent problem among cancer patients receiving chemotherapy and 
radiation therapy (Abu Obead, Batiha, Al-Jauissy, Alhalaiqa, & AlBashtawy, 
2014; Abu Obead et al.,2014a; Erturk, Yildirim, Kilic, Ozer, & Aykar, 2015; 
Ho et al., 2015; Iwase et al., 2015; Langston, Armes, Levy, Tidey, & Ream, 
2013). Cancer Related Fatigue (CRF) is considered the most distressing 
symptom experienced by cancer patients (Weis, Horneber, & SpringerLink, 
2015). The prevalence of fatigue increases substantially when patients 
receive chemotherapy or radiotherapy (Huijer, Abboud, & Doumit, 2012; 
Stone et al., 2000). Moreover, cancer patients receiving chemotherapy report 
more severe fatigue in comparison to patients receiving other treatment 
modalities (Manir et al., 2012; Schmidt et al., 2012). 
There are several factors associated with CRF. According to Stobäus, Müller, 
Küpferling, Schulzke, and Norman (2015), low protein intake, gender, 
nausea, vomiting, insomnia and age are considerable risks for CRF. 
Furthermore, sleep experience, patient age and different types of cancer were 
significantly associated with CRF (Nunes, Jacob, Adlard, Secola, & 
Nascimento, 2015).  
Fatigue commonly has a negative impact on the patients’ Quality of Life 
(QOL). For example, patients with Parkinson’s disease with a higher score of 
fatigue suffered from more disturbance in their quality of life (Havlikova et 
al., 2008). CRF has a profound influence on patients QOL. It affects patients 
functionality and their moods (Yeo, Yeo, & Cannaday, 2015). 
Kitamura et al. (2015) argued that patients receiving chemotherapy had 
biochemical changes in their brain that affect their cognitive and 
psychological status and increase their anxiety levels. Moreover, several 
studies indicate that patients receiving chemotherapy had significant levels 
of depression and anxiety (Akechi et al., 2012; Iconomou et al., 2008; 
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Pandey et al., 2006) 
Jordanian cancer patients have a higher level of distress as compared to the 
findings in other cultures (Omran, Saeed, & Simpson, 2012).There is little 
known about the impact of depression and anxiety on CRF in patients 
receiving chemotherapy in the Jordanian community. This study aims to fill a 
gap in the existing body of knowledge by exploring the prevalence of fatigue 
as a side effect of cancer chemotherapy. This study also aims to make known 
the impact of depression and anxiety on fatigue among Jordanian patients 
receiving chemotherapy. The study will answer the following questions: 
What is the prevalence of fatigue among Jordanian cancer patients who 
receive chemotherapy as their primary treatment? 
What is the impact of chemotherapy on fatigue levels among cancer patients 
who receive chemotherapy? 
What is the effect of depression and anxiety levels on patient fatigue levels 
among Jordanian cancer patients receiving chemotherapy? 
The Integrated Fatigue Model (IFM) was used to guide this study. This 
framework permits multiple disciplinary perspectives, definitions, and 
theories about fatigue to be analyzed. This framework is described as a core 
of the subjective (perceptual) and objective (physiological, biochemical and 
metabolic, and behavioral) indicators of fatigue reported in the literature. At 
the center of the framework are the metabolic, neuro-physiological, 
situational, and developmental stressor patterns that may cause or modulate 
the signs and symptoms of fatigue (Piper, Lindsey, & Dodd, 1987). 
Psychological factors, including usual response to stressors, depression, 
anxiety, motivation, distraction, boredom, beliefs, and attitudes, may 
influence fatigue. This study will focus on the psychological symptoms 
related to depression and anxiety (See Figure 1). 
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Figure I: Integrated Fatigue Model 
 
Method  
Research design  
 The design of this study was a one group before and after quasi-
experimental design. This design is appropriate to explore the impact of 
chemotherapy on fatigue. Moreover, it also helped to identify other 
psychological variables that affect fatigue in cancer patient receiving 
chemotherapy. 
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Sample  
 The participants of the study were recruited using a convenience 
sampling technique. Each participant was required to be: (a) above 18 years 
of age, (b) free from severe mental or cognitive impairment (c) receiving 
chemotherapy as a primary treatment, (d) able to read, write and understand 
Arabic, (e) free of cardiac, respiratory and medical illnesses and (f) able to 
give consent to participate in this study. All participants agreed to participate 
and were able to complete the study tool.  
 
Instruments 
 Piper fatigue scale (PFS) is a subjective multidimensional instrument 
that measures fatigue in patients and assesses the amount and level of 
fatigue, degree of stress or interference experienced in daily activities, and 
feelings or sensations that indicate fatigue. 
 PFS is composed of 22 items with numerical scales. Each one is rated 
from 0 to 10 were higher score represent more fatigue severity. These items 
are used to measure subjective fatigue from four dimensions perspective: 
behavioral; affective; sensory and cognitive.  The aggregates are used to 
calculate the total fatigue score and the four sub-scale/dimensional scores. 
Five additional questions are recommended to be kept in the scale because 
these questions provided qualitative data. One item in particular gives a 
categorical way in which to assess fatigue duration among respondents, other 
items asked about causes of fatigue, best thing to alleviate it, and the 
experience of any other symptoms. The scores of PFS are categorized into 
four levels: 0 none, 1-3 mild, 4-6 moderate and 7-10 severe. The Arabic 
version of PFS was tested and found reliable. The internal consistency of the 
Arabic version of PFS was established in other studies (Abu Obead et 
al.,2014). Moreover, a pilot study was performed before conducting this 
study, which revealed that the Cronbach alpha for the total score was (alpha 
=0.965). It also revealed that for the four dimensions, behavioral, affective, 
sensory, and cognitive dimension were (alpha =0.896, 0.96, 0.96, and 0.91 
respectively). 
 The Hospital Anxiety and Depression Scale (HADS) is a widly used 
instrument to evaluate depression and anxiety (psychological distress) among 
hospitalized subjects. This questionnaire is composed of 14 items, seven of 
which measure anxiety and seven measure of depression. Each item is rated 
on a scale of 0 (best status) to 3 (worst status). The possible scores for 
depression and anxiety range from 0 to 21 with normal scores ranging from 
0-7 and scores of 8-10 indicating borderline depression or anxiety. A score of 
11 or more indicate significant psychological morbidity. The reliability of 
this questionnaire was established in a pilot study before conducting this 
research. Both anxiety and depression have good internal consistency (alpha 
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= .785 and .841 respectively). 
 
Results  
 A total of 78 participants completed all phases of the study. Among 
these participants, 56 participants (83%) were from Al-Bashir hospital and 
22 (28%) participants were from King Abdullah University Hospital (n=78). 
All participant met the inclusion criteria, agreed to participate, and were able 
to complete the study measurements. (See table 1). 
 
Prevalence of Fatigue 
 The PFS was administrated twice, the first time before chemotherapy 
and a second time after one week of chemotherapy. All subscales scores were 
increased as follows: the mean total PFS scores increased from 3.76 (SD= 
1.98) to 5.71 (SD= 2.19) after one week of taking chemotherapy. The 
increase in subscales was as follow: the mean scores for behavioral subscale 
increased from 3.98 (SD=2.25) to 5.95 (SD=2.43), sensory subscale 
increased from 4.21 (SD=2.28) to 6.46 (SD=2.56), affective subscale 
increased from 3.83 (SD=2.29) to 5.93 (SD=2.68), and cognitive subscale 
increased from 3.09 (SD=2.03) to 4.66 (SD=2.21). This increase in fatigue 
scores is reflected by the increase in the severity of fatigue. About 60.3% of 
the participants complained of mild fatigue before treatment according to 
PFS cut off points; this percentage decreased to 25.6% after treatments. 
However, 28.2% of the participants complained of moderate fatigue before 
treatments; this ratio rose to 42.3% after treatments. About 10.3% of 
participants complained of severe fatigue before treatment, and this 
percentage also increased to 30.8% of participants after one week of 
treatment. The increase in fatigue scores was seen in all PFS subscales (See 
table 2). 
Table 1: Socio-demographic characteristics of the sample (n=78) 
Range SD Mean % Frequency Category Character 
 
 
 
 
 
 
65.4 
34.6 
51 
27 
Male 
Female 
Sex 
 
19-67 14.11 44.76    Age in years 
 
 
 
 
 
 
 
 
 
 
 
 
65.4 
21.8 
10.3 
2.6 
51 
17 
8 
2 
Married 
Single 
Widow 
Divorced 
Marital Status 
 
 
 
 
 
 
 
 
 
 
 
39.7 
23.0 
37.1 
31 
18 
29 
1-10 years 
11-12 years 
>12 years 
Level of Education 
 
 
 
 
 
 
 
 
 
 
42.3 
39.7 
17.9 
33 
31 
14 
Unemployed 
Skilled work 
Unskilled  work 
Occupation 
 
 
100-900 
 
 
119.22 
 
 
246.15 
 
 
 
 
 
 
 
 
 
 
Monthly Income 
(JD) 
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 The following responses were obtained from the qualitative data. 
When participants were asked about what they believe is most directly 
contributing to or causing their fatigue, most participants indicated that 
chemotherapy was the cause of their fatigue. When participants were asked 
the best thing they have found to relieve their fatigue, the answer was 
praying, reading Holly Koran, rest, and some of them said that fatigue was 
relieved by light activities. All participants believed that stopping 
chemotherapy is the best thing to relieve fatigue. When participants were 
asked to describe their fatigue, most of them answered that fatigue is the 
most distressing symptom affecting their lives.  
 
Impact of Chemotherapy on Fatigue  
 Fatigue was measured before and after taking chemotherapy. A 
paired-sample t-test was used for total scores and each subscale of PFS. The 
result showed a significant difference between respondents’ mean total 
scores of fatigue pre and post chemotherapy as measured by the total PFS 
questionnaire (t = -5.37 df = 77, P< 0.05). In addition, significant differences 
were found between pre and post chemotherapy scores for all subscales, 
namely behavioral, affective, sensory, and cognitive dimensions (t = -5.22,-
5.04,-5.19,-4.67 df =77 respectively, P< 0.05). (See table 3). 
 
Table 3: Results of Paired–Sample t-test for Fatigue Scores 
PFS subscale Time Mean SD t df Sig 
Behavioral 
 
Pre chemotherapy 
Post chemotherapy 
3.98 
5.95 
2.25 
2.43 
-5.224 77 
 
0.000 
 
Affective Pre chemotherapy 
Post chemotherapy 
3.83 
5.93 
2.29 
2.68 
-5.035 77 0.000 
Sensory Pre chemotherapy 
Post chemotherapy 
4.22 
6.46 
2.28 
2.56 
-5.192 77 0.000 
Cognitive 
 
Pre chemotherapy 
Post chemotherapy 
3.09 
4.66 
2.03 
2.21 
-4.665 77 0.000 
 
Total PFS Pre chemotherapy 
Post chemotherapy 
3.76 
5.71 
1.98 
2.19 
-5.367 77 0.000 
 
 
Table 2: Pre-Treatment and Post-Treatment Changes in PFS 
  Behavioral Sensory Affective Cognitive Total 
PFS 
Pre 
treatment 
Mean 3.98 4.21 3.83 3.09 3.76 
SD 2.25 2.28 2.29 2.03 1.98 
Post 
treatment 
Mean 5.95 6.46 5.93 4.66 5.71 
SD 2.43 2.56 2.68 2.21 2.19 
 Highest 
Score 
10 10 10 10 10 
European Scientific Journal November 2015 edition vol.11, No.33 ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
46 
Factors Affect Fatigue Score 
 Spearman rho was used to assess the relationship between fatigue 
scores after chemotherapy and categorical variables. The results showed no 
relationship between sex, marital status and fatigue (r= 0.016, 0.005 
respectively, p>0.05). Furthermore, the Pearson Product Moment Correlation 
was used to test the significant relationships between fatigue and continuous 
variables. The further analysis used multiple stepwise regressions to test the 
relationship between fatigue score and psychological symptom (depression 
and anxiety) and demographic variables (age, educational level and income). 
The Pearson Product Moment Correlation revealed no significant 
relationship between fatigue scores after chemotherapy as measured by PFS 
and age, educational level and income. However, there was a significant 
relationship between fatigue, depression and anxiety (r=0.68, r= 0.67 
respectively, p<0.1) (See table 4). 
Table 4: Pearson Product Moment Correlation 
Variables PFS scores 
Age -0.111 
Educational Level -0.006 
Income -0.098 
Anxiety 0.67* 
Depression 0.68* 
*P< 0.01 
 
 The stepwise multiple regression tests revealed that depression was a 
significant predictor of variance in fatigue and explained about 46% 
(Beta= .398, p<0.01) of the variance in the total fatigue score. It also 
revealed adding anxiety to the model can explain another 3.6% (Beta=.34, 
p<0.05) of this variance (See table 5). 
 
Table 5: Stepwise Multiple Regression  
Model R R2 Adjusted R2 
Std. Error of the 
Estimate 
Change Statistics 
R2 
Change 
F 
Change df1 df2 
Sig F 
Change  
1 .681a .463 .456 1.61850 .463 65.611 1 76 .000  
2 .706b .499 .486 1.57395 .036 5.363 1 75 .023  
a. Predictors: (Constant), depression 
b. Predictors: (Constant), depression, anxiety 
c. Dependent Variable: PIPER FATIGUE SCALE  
 
Discussion and Analysis 
 There was a significant difference between PFS scores before and 
after chemotherapy treatments; this difference was reflected in the increase 
of prevalence of total PFS and the subscales mean scores. There were 
significant relationships between fatigue scores as measured by PFS and both 
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depression and anxiety. Furthermore, depression and anxiety were significant 
predictors of fatigue. 
 
Prevalence of fatigue in patient receiving chemotherapy 
 The mean total PFS score was 3.76 (SD= 1.98), and after one week 
of receiving the chemotherapy, it was increased to 5.71 (SD= 2.19). 
Accordingly, it is clear that the mean fatigue score increased by 52%. All 
patients report fatigue with 73.1% reporting moderate to high level of fatigue 
after chemotherapy comparing to 38.5% before chemotherapy. It is clear that 
the level of fatigue increased after chemotherapy. 
Prevalence of CRF varies widely in the studies depending on how fatigue is 
assessed and the strictness of the used criteria (Minton & Stone, 2008; Prue, 
Rankin, Allen, Gracey, & Cramp, 2006). According to Karthikeyan, Jumnani, 
Prabhu, Manoor, and Supe (2012), patients receiving chemotherapy suffered 
from higher fatigue score as compared to other treatment modalities. The 
level of fatigue increased significantly with more chemotherapy cycles 
(Goedendorp et al., 2012; Spichiger et al., 2011). There are several 
explanations for the prevalence of fatigue among cancer patients who receive 
chemotherapy. It was found that chemotherapy is associated with 
biochemical changes in the brain that result in psychosocial and cognitive 
changes (Kitamura et al., 2015). These changes could result in an increased 
fatigue level in patients receiving chemotherapy. 
The complexity of the phenomenon of fatigue could be used to explain the 
increase in fatigue score post-treatment with chemotherapy. Fatigue is a 
multidimensional, multifaceted, and subjective condition. Fatigue can be 
caused by many factors, both intrinsic to the patients and extrinsic such as 
therapeutic intervention (Piper et al., 1987). It has been known that fatigue is 
the utmost reported distressing symptom among patients receiving 
radiotherapy and chemotherapy (Huijer et al., 2012; Stone et al., 2000). The 
metabolic, neurophysiological, situational, and developmental stressor 
patterns which are related to use of chemotherapy can cause and modulate 
the signs and symptoms of fatigue. 
 
Depression and anxiety as predictor of CRF 
 The change in level of psychological symptoms (depression and 
anxiety) to morbid depression and anxiety may account for the increase in 
the prevalence of fatigue. There was a significant relationship between 
fatigue and the severity of psychological symptoms (anxiety and depression). 
Based on regression analysis, depression was a significant predictor of 
variance in fatigue and explains about 46% of this variance. On the other 
hand, anxiety explains 3.6% of the variance in fatigue.  
Depression was found to be a significant predictor of fatigue in several 
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research studies (Mota, Pimenta, & Caponera, 2012; Pertl, Hevey, Collier, 
Lambe, & O’Dwyer, 2014). Depression is associated with sleep disturbance, 
and it affects the quality and the quantity of sleep (Gupta, Dahiya, & Bhatia, 
2009). Sleep disturbance and interruption could result in increased tiredness, 
and consequently, increased fatigue. Moreover, depression results in a lack of 
energy and change of appetite which could increase the level of fatigue.   
The result of this study is congruent with previous studies. In large systemic 
review with a combined sample size of 12,103, anxiety and depression were 
associated with fatigue in most of the studies (Brown & Kroenke, 2009). 
Anxiety may cause overwhelming fatigue as a result of the maladaptive 
response. The maladaptive response could exaggerate the fatigue 
manifestations and increase the fatigue level.  
The perspective of more conservative Arabic Jordanian community for 
cancer is different from other populations. The network of social support 
system and the strong religious believes may interfere with the feeling of 
anxiety. The emotional distress that results from feeling the loss can 
misrepresent and amplify fatigue. The vantage point of the qualitative part of 
PFS indicates that participant may feel relief when they are praying and 
reading the Holy Koran. 
 
Implications   
 There are several implications for this study. For instance, health 
team members could utilize a symptom-oriented approach in the assessment 
and management of fatigue with more focus on patients suffering from 
depression and anxiety. Furthermore, the result could be used as evidence 
related practice to educate cancer patients about how to manage fatigue.  
Moreover, the results could help in the development of a protocol for the 
management and care of cancer patients suffering from fatigue. It will also 
help in raising the consciousness of all health team members involved in the 
care of cancer patients with regards to fatigue and helping patients deal with 
it.   
 
Conclusion 
 The sample size was a major limitation since only 78 participants 
were able to complete this study. The results of the inferential statistics must, 
therefore, be interpreted with extreme caution, as generalizability is not 
granted due to the use of convenience sample.  
 Despite the limitation of this study and the facts about cancer and 
chemotherapy, it can be concluded that fatigue is a prevalent symptom 
among cancer population receiving chemotherapy. Psychological factors 
(depression and anxiety) were identified as possible contributors to fatigue 
among cancer patients who receive chemotherapy. 
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 The Piper Fatigue Scale is a highly reliable instrument for measuring 
fatigue in cancer patients and can be used for efficient assessment of fatigue 
in this population. These significant predictors can be used in the assessment 
of high-risk patients in a symptom-oriented approach for finding an 
individualized solution to the problem.  
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